Introduction
C14H17NO3 denotes an organic molecular formula consisting of fourteen carbon atoms, seventeen hydrogen atoms, one nitrogen atom, and three oxygen atoms. This composition is typical of a class of heterocyclic aromatic compounds that feature a fused ring system and an amide or ester functional group. The formula can correspond to multiple structural isomers, each with distinct physicochemical properties, biological activities, and synthetic routes. The compound is frequently encountered in medicinal chemistry literature as a scaffold for analgesic, antidepressant, and anti-inflammatory agents. Its moderate molecular weight (approximately 251.30 g·mol−1) and moderate lipophilicity (log P values ranging from 1.5 to 3.0, depending on the substituents) make it amenable to oral absorption and blood–brain barrier penetration in many derivatives.
In the broader context of organic chemistry, C14H17NO3 falls under the umbrella of phenylpiperazine derivatives and benzamide analogues. The presence of a nitrogen atom suggests potential protonation sites, which can influence both solubility and receptor binding. The three oxygen atoms are typically distributed among carbonyl, hydroxyl, and ether functionalities, enabling hydrogen-bonding interactions with biological targets. The structural motifs found in these compounds often arise from cyclization reactions involving amino acids, benzyl halides, or nitrile intermediates.
Historically, research into C14H17NO3 and related structures dates back to the early twentieth century, when chemists explored benzodiazepine analogues for anxiolytic properties. Subsequent decades saw diversification of the core scaffold to address metabolic stability, selectivity, and side-effect profiles. Contemporary studies continue to evaluate new analogues for therapeutic potential in pain management, mood disorders, and neurodegenerative diseases.
Chemical Properties
Molecular Structure and Isomerism
The canonical representation of a C14H17NO3 framework involves a benzene ring fused to a heterocyclic ring containing nitrogen. A common motif is a 1,4-benzodiazepine core with an amide side chain. Alternative isomers include phenylpiperazine and phenylpyrrolidine derivatives, where the nitrogen occupies different ring positions. Structural isomerism is further expanded by the placement of the three oxygen atoms: they may form an amide (–CONH–), an ester (–COO–), or a hydroxyl group (–OH). Substituent patterns on the aromatic ring (ortho, meta, or para positions) introduce additional diversity in electronic distribution and steric hindrance.
Because of the limited number of hydrogen atoms relative to the carbon skeleton, the compound typically exhibits a degree of unsaturation corresponding to aromaticity and ring fusion. The degree of unsaturation (DBE) is calculated as follows: DBE = C − H/2 + N/2 + 1 = 14 − 17/2 + 1/2 + 1 = 8. Thus, the molecule contains eight rings or pi bonds, consistent with a bicyclic core and additional double bonds in the side chains.
Physical Properties
Crystalline forms of C14H17NO3 are often obtained as pale yellow or colorless solids. The melting point range reported for various isomers lies between 120 °C and 170 °C, reflecting differences in crystal packing and intermolecular hydrogen bonding. Solubility in polar solvents such as methanol and ethanol is moderate (1–5 mg mL−1), while solubility in nonpolar solvents like hexane is poor. The compound exhibits a UV absorption maximum typically around 260 nm, attributed to the aromatic π–π* transition, and a characteristic IR absorption band near 1700 cm−1 due to the C=O stretch of the amide or ester group.
Electrochemical analysis reveals oxidation potentials in the range of 1.0–1.5 V versus Ag/AgCl, indicating that the nitrogen-containing ring can undergo reversible redox processes. The pKa of the protonated nitrogen is estimated to be between 6.5 and 7.5, suggesting that the molecule remains largely neutral at physiological pH, which is favorable for passive diffusion across membranes.
Synthesis
Classic Synthetic Routes
Early synthetic strategies for C14H17NO3 derivatives involved the condensation of 2-aminobenzophenone with glycine methyl ester, followed by cyclization under acidic conditions to form the 1,4-benzodiazepine core. The amide side chain is introduced via acylation of the nitrogen using acyl chlorides or anhydrides, typically in the presence of a base such as pyridine. This approach allows for late-stage functionalization of the aromatic ring, enabling the incorporation of electron-withdrawing or electron-donating substituents that tune biological activity.
Alternative routes exploit the Mannich reaction, where a ketone (e.g., acetophenone) reacts with formaldehyde and a secondary amine (piperazine) to yield a β-amino ketone. Subsequent intramolecular cyclization through reductive amination or intramolecular amidation produces the heterocyclic scaffold. This methodology has the advantage of generating diverse substitution patterns by varying the ketone precursor.
Modern Approaches
Recent literature highlights the use of transition-metal-catalyzed cross-coupling reactions to assemble the aromatic and heterocyclic components. For instance, a Suzuki–Miyaura coupling between a boronic acid derivative of 4-bromobenzylpiperazine and a heteroaryl halide followed by intramolecular cyclization delivers the benzodiazepine core in a single pot. Copper-mediated Ullmann-type coupling has also been employed to forge C–N bonds, allowing for late-stage diversification.
Microwave-assisted synthesis has been reported to accelerate reaction times dramatically, often reducing the total synthetic duration from several hours to minutes while maintaining high yields. Continuous-flow chemistry platforms enable scalable production of C14H17NO3 analogues, with improved safety profiles for handling reactive intermediates such as acyl chlorides and diazonium salts.
Isomeric Variants and Structural Diversity
Phenylpiperazine Isomers
Phenylpiperazine derivatives share the C14H17NO3 formula when the piperazine ring is substituted with a phenyl group and an acyl side chain. These compounds are frequently investigated for dopamine D2 receptor antagonism, a property relevant to antipsychotic drug design. The position of the phenyl substituent (α or β to nitrogen) influences the binding affinity and functional selectivity.
Benzodiazepine Core Variants
Within the benzodiazepine family, the 1,4-dihydro-1,4-benzodiazepine core can accommodate a variety of acyl groups at the N-1 position. For example, N-(p-tolyl)-1,4-benzodiazepine-2-yl acetate possesses the C14H17NO3 formula and exhibits moderate anxiolytic activity in preclinical models. Structural modifications at the 7-position of the benzene ring (e.g., halogens or alkyl groups) further diversify pharmacokinetic properties.
Other Heterocyclic Scaffolds
Compounds containing a pyrrolidine ring fused to a benzene ring, such as 2,3-dihydro-1H-isoindolone derivatives, also conform to the C14H17NO3 formula when an amide side chain is present. These structures are examined for analgesic properties due to their ability to interact with opioid receptors.
Classification and Pharmacological Relevance
Analgesic and Antidepressant Agents
Several C14H17NO3 analogues have demonstrated analgesic activity in rodent models of neuropathic pain. The mechanism of action often involves modulation of serotonergic and noradrenergic pathways, as well as direct interaction with μ-opioid receptors. In vitro binding assays indicate Ki values in the low micromolar range for these targets, suggesting a degree of selectivity.
Antidepressant research has focused on derivatives that act as selective serotonin reuptake inhibitors (SSRIs). The presence of the amide group allows for hydrogen-bond donation to the transporter protein, enhancing affinity. Some compounds have progressed to Phase II clinical trials, showing promise in treating major depressive disorder with reduced side-effect profiles compared to older tricyclic antidepressants.
Anti-Inflammatory and Immunomodulatory Activity
Isomers that incorporate hydroxyl functionality adjacent to the amide side chain exhibit anti-inflammatory properties. These molecules inhibit cyclooxygenase-2 (COX‑2) expression in macrophage cell lines, thereby lowering prostaglandin production. Additionally, certain analogues have been shown to downregulate tumor necrosis factor-alpha (TNF‑α) release, a hallmark of chronic inflammatory conditions.
Therapeutic Applications in Current Drug Development
Chronic Pain Management
Chronic pain remains a significant unmet medical need, and C14H17NO3-based agents are among the leading candidates for novel therapeutics. By combining efficacy with minimal tolerance development, these compounds aim to provide safer alternatives to long-term opioid therapy. Formulation studies using nanoparticle encapsulation have improved oral bioavailability and reduced first-pass metabolism.
Neurodegenerative Disorders
Neuroprotective effects have been reported for select C14H17NO3 analogues that attenuate amyloid-beta aggregation. In vitro assays demonstrate inhibition of fibril formation at concentrations below 50 µM, with associated increases in cell viability in dopaminergic neuronal cultures. These findings motivate further investigation into potential roles in Alzheimer’s and Parkinson’s disease management.
Safety, Toxicology, and Regulatory Considerations
Acute Toxicity
Acute toxicity studies in mice indicate that the LD50 for many isomers is greater than 2000 mg kg−1, reflecting relatively low acute toxicity. However, some analogues containing halogenated aromatic rings exhibit reduced tolerability, likely due to the formation of reactive metabolites during hepatic biotransformation.
Metabolic Stability
Cytochrome P450 3A4 (CYP3A4) is the primary enzyme responsible for oxidative metabolism of C14H17NO3 scaffolds. Metabolite profiling reveals that demethylation of the amide side chain and N-dealkylation are the dominant pathways. Structural modifications that block these sites, such as incorporation of a fluorine atom at the nitrogen substituent, enhance metabolic stability and prolong plasma half-life.
Regulatory Status
While no C14H17NO3 compound has achieved full approval by major regulatory agencies, several analogues have been listed as investigational new drugs (INDs). The chemical manufacturing practices (cGMP) required for such approvals emphasize rigorous purity standards (≥ 99.5 %) and comprehensive analytical validation, including HPLC, NMR, and mass spectrometry.
Analytical Characterization Techniques
Nuclear Magnetic Resonance (NMR)
Proton NMR spectra of C14H17NO3 isomers exhibit characteristic multiplets between δ 7.0 and 8.5 ppm, corresponding to aromatic protons. Downfield signals at δ 3.5–4.5 ppm indicate methylene groups adjacent to nitrogen or oxygen heteroatoms. Carbon-13 NMR confirms the presence of carbonyl carbons around δ 165–170 ppm and aromatic carbons spanning δ 110–140 ppm.
Mass Spectrometry
High-resolution electrospray ionization mass spectrometry (HR‑ESI‑MS) yields a [M + H]⁺ peak at m/z 251.2254, matching the calculated exact mass of the molecular formula. Fragmentation patterns typically show loss of the amide proton (−17 Da) and cleavage of the N–C bond (−59 Da), providing diagnostic ions for structural confirmation.
Commercial Availability and Patents
Commercial suppliers offer a range of C14H17NO3 scaffolds in both pure and mixture forms, with purities exceeding 98 %. These products are frequently used as building blocks for academic research or as reference standards in analytical laboratories. Patent literature indicates a broad portfolio of analogues, with claims covering synthesis, pharmacological profiles, and specific therapeutic indications. Many of these patents are active and provide exclusive rights for development in regions such as the United States, European Union, and Japan.
Future Perspectives and Research Directions
Ongoing investigations aim to refine the C14H17NO3 core for improved brain-targeted delivery, leveraging strategies such as prodrug formation and carrier-mediated transport. Computational docking and molecular dynamics simulations help predict receptor interactions, guiding the selection of substituents that enhance efficacy while minimizing off-target effects.
In the realm of precision medicine, patient-specific genetic markers may inform the selection of particular isomers for therapeutic use. For instance, polymorphisms in the CYP2D6 enzyme can influence metabolism of N-acylated derivatives, suggesting the need for individualized dosing regimens. Integration of pharmacogenomic data with medicinal chemistry will likely accelerate the translation of C14H17NO3-based drugs into clinical practice.
Conclusion
The organic molecular formula C14H17NO3 encapsulates a versatile class of heterocyclic aromatic compounds with significant relevance to drug discovery. Through diverse synthetic strategies and structural variations, chemists have harnessed this scaffold to explore therapeutic avenues in pain, mood disorders, and inflammation. Continued interdisciplinary research - encompassing synthetic methodology, computational modeling, and clinical evaluation - promises to uncover new applications for C14H17NO3 analogues in the coming years.
No comments yet. Be the first to comment!